eb, I share that opinion because i think PPHM would have send out a misleading PR if the one in which they mention statistical significance in Sunrise for overall survival of Bavituximab+Docetaxel over Placebo+Docetaxel would only imply to a sub-group.
In that case this PR would let the investors believe they have a result over the COMPLETE DATA SET (proven by the fact that I myself and many with me believe that from the PR text, including yourself) while it would only be about a sub-set.
I don't think PPHM is in a situation where they can afford that kind of stunts given that also the complete scientific community involved with PS Targetting and combo's with anti-PS are reading along.
I also think that the drop in short interest points to the expectation of a possible short term 'sudden event' where the shorts do not want to be in position. In general they are informed because I think part of this shorting may be coming from parties that have close information of what is going on and can use channels to short that do not directly lead to them. That is why the shorts seem to be always right because otherwise I have no explanation in that we probably all agree that "coincidence" doesn't really apply here.
Short Interest dropped below 0.5% of outstanding shares.
News 
Market Data 
Discover 
